CTI Biopharma Corp
F:CEPS
Fundamental Analysis

Revenue & Expenses Breakdown
CTI Biopharma Corp
Balance Sheet Decomposition
CTI Biopharma Corp
Current Assets | 86.5m |
Cash & Short-Term Investments | 59m |
Receivables | 23m |
Other Current Assets | 4.5m |
Non-Current Assets | 25.8m |
PP&E | 1.9m |
Intangibles | 22.7m |
Other Non-Current Assets | 1.2m |
Free Cash Flow Analysis
CTI Biopharma Corp
USD | |
Free Cash Flow | USD |
Earnings Waterfall
CTI Biopharma Corp
Revenue
|
75.8m
USD
|
Cost of Revenue
|
-4.5m
USD
|
Gross Profit
|
71.3m
USD
|
Operating Expenses
|
-125.2m
USD
|
Operating Income
|
-53.9m
USD
|
Other Expenses
|
-15.3m
USD
|
Net Income
|
-69.2m
USD
|
CEPS Profitability Score
Profitability Due Diligence
CTI Biopharma Corp's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
CTI Biopharma Corp's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
CEPS Solvency Score
Solvency Due Diligence
CTI Biopharma Corp's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
CTI Biopharma Corp's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CEPS Price Targets Summary
CTI Biopharma Corp
Dividends
Current shareholder yield for CEPS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?